KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ClearPoint Neuro (CLPT) Common Equity (2018 - 2025)

ClearPoint Neuro (CLPT) has disclosed Common Equity for 13 consecutive years, with $28.0 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 10.36% to $28.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $28.0 million through Dec 2025, up 10.36% year-over-year, with the annual reading at $28.0 million for FY2025, 10.36% up from the prior year.
  • Common Equity hit $28.0 million in Q4 2025 for ClearPoint Neuro, up from $15.9 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $48.8 million in Q4 2021 to a low of $15.9 million in Q3 2025.
  • Historically, Common Equity has averaged $33.0 million across 5 years, with a median of $32.4 million in 2023.
  • Biggest five-year swings in Common Equity: skyrocketed 29510.74% in 2021 and later tumbled 45.26% in 2025.
  • Year by year, Common Equity stood at $48.8 million in 2021, then decreased by 24.39% to $36.9 million in 2022, then crashed by 42.6% to $21.2 million in 2023, then increased by 19.91% to $25.4 million in 2024, then rose by 10.36% to $28.0 million in 2025.
  • Business Quant data shows Common Equity for CLPT at $28.0 million in Q4 2025, $15.9 million in Q3 2025, and $19.7 million in Q2 2025.